Search Results
Showing Results for checkpoint inhibitors
At ASCO 2025, cervical cancer took centre stage in gynecologic oncology with data showing how immunotherapy is redefining the treatment landscape. Trials such as KEYNOTE-826 and KEYNOTE-A18 demonstrated meaningful gains in survival, while emerging antibody–drug conjugates point to a new wave of personalised therapy for this historically underserved disease.
Dr Frank Sinicrope presented results from the ATOMIC trial at #ASCO25, showing that adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in stage III dMMR colon cancer. With no major safety concerns, the findings support chemo-immunotherapy as a new standard of care for this patient group.
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1 Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2 Head and neck squamous cell carcinoma (...
Liquid biopsy: Initial concepts and application in solid tumours The US National Cancer Institute defines liquid biopsy (LB) as ‘a test done on a sample of blood to look for cancer cells from a tumour that are circulating in the ...
Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise ...
“By engaging in research early, young oncologists can contribute to scientific discovery” Q1. What inspired you to pursue a career in oncology? Initially, as a gastroenterologist, I experienced many benign diseases and endoscopic procedures, but oncology was what interested me ...
It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This issue highlights the remarkable progress and innovation shaping the fields of oncology and haematology, featuring articles that delve into both emerging therapies ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
Metastatic castration-resistant prostate cancer (mCRPC) represents the most formidable stage of prostate cancer (PCa) and is responsible for the majority of PCa-related mortalities. This advanced form of the disease typically evolves from less aggressive stages.1 PCa is broadly categorized into ...
Oesophageal cancer is the eighth most commonly diagnosed cancer and is the sixth leading cause of cancer death worldwide.1,2 Worldwide, around 604,100 new instances of oesophageal cancer were recorded in 2020, leading to approximately 544,100 deaths. This translates to a standardized incidence rate ...
Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The ...
In this interview, Dr Michael K. Gibson (Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA), an expert in head and neck and gastrointestinal (GI) oncology shares his personal journey, reflecting on how early experiences with cancer shaped his ...
The COVID-19 pandemic accelerated the development of mRNA technologies, most notably with the creation of mRNA vaccines targeting SARS-CoV-2. While these vaccines helped control the pandemic, their potential may extend beyond infectious diseases, with growing interest in their potential application ...
We’re thrilled to welcome Dr. Ken Kato (National Cancer Center Hospital, Tokyo, Japan) to discuss the unique advantages and challenges of conducting cancer research in Japan. Key advantages include robust regulatory support, streamlined trial approvals and strong collaboration with ...
Trifluridine/tipiracil (FTD/TPI) is a novel oral formulation of two drugs with promising results in the treatment of metastatic colorectal cancer (mCRC).1 Trifluridine is a thymidine-based nucleoside analogue that, after intracellular phosphorylation, gets incorporated into DNA, causing DNA dysfunction.2 ...
The ATHENA trial evaluated the effectiveness of rucaparib (RUCA) monotherapy (MONO) and rucaparib combined with nivolumab (NIVO) (COMBO) in patients with advanced high-grade ovarian cancer (AHGOC). In the MONO arm, rucaparib showed sustained progression-free survival (PFS) of 20.2 months after first-line ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
